Novo shares were rallying after it announced late Monday that the U.S. Food and Drug Administration (FDA) approved a pill version of Wegovy—the weight-loss version of the Danish company’s groundbreaking Ozempic drug and a competitor to Eli Lilly’s Zepbound.

The US Food and Drug Administration has approved a pill version of the weight-loss drug Wegovy, according to maker Novo Nordisk.

In a clinical trial funded by Novo Nordisk, 205 participants took the Wegovy pill, and 102 took a placebo.